DIAGNOSWISS

DiagnoSwiss ambitions to become a recognised innovative force in life sciences. Their aim is to provide technical solutions for fast diagnosis and prognosis as well as for target proteins identification. To reach this aim, DiagnoSwiss currently develops two lines of products, namely: disposable polymer µ-chips and gel electrophoresis equipment for protein purification. In a second step of development, DiagnoSwiss will also merge these two products to develop a global solution for large-scale pr... otein screening in proteomics. DiagnoSwiss’ core technology relies on protein analysis with microfabricated separation methods and affinity assays, and creates high-throughput proteomics platforms in the microtiter-plate format. DiagnoSwiss is filling the gap between high-throughput screening platforms and proteomics for advanced drug discovery. Mass production of low cost polymer micro-chips with specific surface treatment and ultra-fast electrophoretic purification of proteins in free flowing solution are the key elements of DiagnoSwiss’ innovating and proprietary technology. Their approach consists in maintaining the proteins in solution throughout the analysis of native biological samples, thereby increasing the separation rate, facilitating automation and optimising mass spectrometry identification. DiagnoSwiss is currently developing integrated protein analytical systems, that include components for fluid handling and coupling to high resolution detection means and that offer a unique alternative to 2D-gel electrophoresis. DiagnoSwiss’ micro-analytical systems will enable high-througput protein discovery, identification of protein structure and activity, as well as affinity testing (protein-protein, protein-small molecule interactions and immunological assays). Different architectures of miniaturized protein biochips will address the present requirements of proteomics-based drug discovery, and will be extended to the field of medical diagnostics. DiagnoSwiss develops new products and applications directly with its customers, and it aims at becoming a leading provider of instrumentation tools for biomarker discovery, protein assays and characterisation. Miniaturisation, automation, parallelism and its subsequent increased throughput provides order-of-magnitude or greater cost reductions and efficiency improvements on several levels. More